Abstract 188P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLS) and B cells. However, the cellular and molecular mechanisms underlying these clinical associations have not been elucidated yet.
Methods
TME composition and TLS quantification were assessed by sequential IHC with αCD3, αCD20, αCD23 and αCD68 antibodies on specimens obtained from patients with primary or locally recurrent STS enrolled and treated at the Careggi Hospital (RESEARCH study). TME transcriptomic profiling was performed using the nCounter Immunology Panel by NanoString. RNA-sequencing and clinical data for 206 STS patients were retrieved from the TCGA SARC project.
Results
IHC of 23 treatment-naïve STS specimens showed higher TLS density and incidence in the group of non-recurrent patients (11/15) compared to patients developing recurrence (2/8; P=0.039). CD8+ T cell, CD20+ B cell and CD23+ follicular dendritic cell densities are higher in the TME of TLS+ STS. CD20 and CD23 (but not CD8) expression is associated to improved recurrence-free survival (RFS) and overall survival (OS) in our cohort. Transcriptomic analysis of 31 treatment-naïve STSs showed that high expression of genes discriminating for germinal center (GC) B cells correlated to the upregulation of Th17-related genes, and decreased expression of M2-like tumor-associated macrophages (TAMs)-related genes. High expression of GC B cell- and Th17 differentiation-related signatures showed associations to longer RFS in our cohort, and to improved OS in the TCGA SARC cohort. Analysis of 5 samples obtained after neoadjuvant radiotherapy (RT) showed reduced expression of IL17A and GC B-related genes while increased TAM-related gene expression, compared to paired biopsies obtained before RT.
Conclusions
Our data identified a prognostic value for Th17-related genes, suggest a potential crosstalk between GC B cells and Th17 cells in coordinating antitumor immune responses, and a potential role for M2-like TAMs (and RT) in inhibiting TLS formation in STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Presenter: Vincent de Jager
Session: Poster session 08
114P - Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma
Presenter: Oscar Gerardo Arrieta Rodriguez
Session: Poster session 08
115P - Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Presenter: Marie Morfouace
Session: Poster session 08
116P - Single-cell RNA sequencing reveals a subset of FSIP1 cancer cells and verified its value of prognosis in lung adenocarcinoma
Presenter: Xiaochen Zhang
Session: Poster session 08
Resources:
Abstract
117P - Methylome and transcriptome profiling of hepatoid adenocarcinoma of the stomach
Presenter: Shirong Zhang
Session: Poster session 08
Resources:
Abstract
118P - Comparative analysis of DNA and RNA-based NGS for detecting MET exon 14 skipping mutation in pan-solid tumor samples
Presenter: Ruijun Cai
Session: Poster session 08
119P - Predicting the pathogenicity of novel fusion genes and explaining reasons using a large language model: A focused assessment
Presenter: Katsuhiko Murakami
Session: Poster session 08
120P - A prospective comparative evaluation of automatic trial match tools in a molecular tumor board
Presenter: Lilia GUEGUEN
Session: Poster session 08